Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis

American Heart Journal

Volumn 160, Issue 4, 2010, Pages 701-714

  Goldberger, Zachary D ^a   Valle, Javier A ^a   Dandekar, Vineet K ^a   Chan, Paul S ^b   Ko, Dennis T ^c   Nallamothu, Brahmajee K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATENOLOL; ATORVASTATIN; CERIVASTATIN; CHLORTALIDONE; COLESTIPOL; DOXAZOSIN; ESTRADIOL; EZETIMIBE; FOLIC ACID; FOSINOPRIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LACIDIPINE; METFORMIN; METOPROLOL; MEVINOLIN; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL;

ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ESSENTIAL HYPERTENSION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; CAROTID ARTERY; ECHOGRAPHY; INCIDENCE; INTIMA; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CAROTID ARTERIES; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUNICA INTIMA;

EID: 77957834662     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.06.029     Document Type: Article

References (60)

1. Granger C.B., and McMurray J.J. Using measures of disease progression to determine therapeutic effect: a sirens' song J Am Coll Cardiol 48 2006 434 437
2. Tardif J.C., Heinonen T., and Orloff D. Vascular biomarkers and surrogates in cardiovascular disease Circulation 113 2006 2936 2942
3. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 1996 605 613
4. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 1999 790 795
5. Krumholz H.M., and Lee T.H. Redefining quality-implications of recent clinical trials N Engl J Med 358 2008 2537 2539
6. Kastelein J.J., and de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies Eur Heart J 29 2008 849 858
7. Duivenvoorden R., de Groot E., and Stroes E.S. Surrogate markers in clinical trials-Challenges and opportunities Atherosclerosis 206 2009 8 16
8. Bots M.L., Hoes A.W., and Koudstaal P.J. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study Circulation 96 1997 1432 1437
9. Chambless L.E., Heiss G., and Folsom A.R. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993 Am J Epidemiol 146 1997 483 494
10. O'Leary D.H., Polak J.F., and Kronmal R.A. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group N Engl J Med 340 1999 14 22
11. Rosvall M., Janzon L., and Berglund G. Incident coronary events and case fatality in relation to common carotid intima-media thickness J Intern Med 257 2005 430 437
12. Robinson K.A., and Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed Int J Epidemiol 31 2002 150 153
13. Rodriguez-Granillo G.A., Agostoni P., and Garcia-Garcia H.M. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound Am J Cardiol 99 2007 5 10
14. Harbord R.M. Meta-regression in Stata Stata J 8 2008 493 519
15. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
16. de Groot E., Jukema J.W., and van Boven A.J. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study Am J Cardiol 76 1995 40C 46C
17. Hedblad B., Zambanini A., and Nilsson P. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study J Intern Med 261 2007 293 305
18. Furberg C.D., Adams H.P. Jr, and Applegate W.B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 90 1994 1679 1687
19. Salonen R., Nyyssönen K., and Porkkala E. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 1995 1758 1764
20. Crouse J.R. III, Byington R.P., and Bond M.G. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol 75 1995 455 459
21. Mercuri M., Bond M.G., and Sirtori C.R. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study Am J Med 101 1996 627 634
22. Hodis H.N., Mack W.J., and LaBree L. The role of carotid arterial intima-media thickness in predicting clinical coronary events Ann Intern Med 128 1998 262 269
23. Smilde T.J., van Wissen S., and Wollersheim H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581
24. Taylor A.J., Kent S.M., and Flaherty P.J. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima-medial thickness Circulation 106 2002 2055 2060
25. Taylor A.J., Sullenberger L.E., and Lee H.J. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
26. Beishuizen E.D., van de Ree M.A., and Jukema J.W. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease Diabetes Care 27 2004 2887 2892
27. Zanchetti A., Crepaldi G., and Bond M.G. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial Stroke 35 2004 2807 2812
28. Crouse J.R. III, Raichlen J.S., and Riley W.A. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 2007 1344 1353
29. Kastelein J.J., van Leuven S.I., and Burgess L. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
30. Kastelein J.J., Akdim F., and Stroes E.S. Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443
31. Bots M.L., Visseren F.L., and Evans G.W. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
32. Howard B.V., Roman M.J., and Devereux R.B. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial JAMA 299 2008 1678 1689
33. Borhani N.O., Mercuri M., and Borhani P.A. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial JAMA 276 1996 785 791
34. Zanchetti A., Rosei E.A., and Dal Palu C. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness J Hypertens 16 1998 1667 1676
35. Hoogerbrugge N., de Groot E., and de Heide L.H. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands Neth J Med 60 2002 354 361
36. Hedblad B., Wikstrand J., and Janzon L. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) Circulation 103 2001 1721 1726
37. Zanchetti A., Bond M.G., and Hennig M. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial Circulation 106 2002 2422 2427
38. Lonn E.M., Gerstein H.C., and Sheridan P. Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) J Am Coll Cardiol 53 2009 2028 2035
39. Mazzone T., Meyer P.M., and Feinstein S.B. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2006 2572 2581
40. Hodis H.N., Mack W.J., and Zheng L. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes Diabetes Care 29 2006 1545 1553
41. Katakami N., Yamasaki Y., and Hayaishi-Okano R. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes Diabetologia 47 2004 1906 1913
42. Meuwese M.C., de Groot E., and Duivenvoorden R. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial JAMA 301 2009 1131 1139
43. Hodis H.N., Mack W.J., and LaBree L. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS) Circulation 106 2002 1453 1459
44. Hodis H.N., Mack W.J., and Lobo R.A. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 135 2001 939 953
45. Zoungas S., McGrath B.P., and Branley P. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial J Am Coll Cardiol 47 2006 1108 1116
46. Bots M.L., and Grobbee D.E. intima-media thickness as a surrogate marker for generalised atherosclerosis Cardiovasc Drugs Ther 16 2002 341 351
47. Espeland M.A., O'Leary D.H., and Terry J.G. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors Curr Control Trials Cardiovasc Med 6 2005 3
48. Lorenz M.W., Markus H.S., and Bots M.L. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis Circulation 115 2007 459 467
49. Wang J.G., Staessen J.A., and Li Y. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials Stroke 37 2006 1933 1940
50. Schoenhagen P., Ziada K.M., and Kapadia S.R. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study Circulation 101 2000 598 603
51. Topol E.J., and Nissen S.E. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease Circulation 92 1995 2333 2342
52. Glagov S., Weisenberg E., and Zarins C.K. Compensatory enlargement of human atherosclerotic coronary arteries N Engl J Med 316 1987 1371 1375 (Pubitemid 17079680)
53. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 2007 257 260
54. Taylor A.J., Villines T.C., and Stanek E.J. Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness N Engl J Med 361 2009 2113 2122
55. Schmid C.H., Stark P.C., and Berlin J.A. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors J Clin Epidemiol 57 2004 683 697
56. Zhao X.Q., Phan B.A., and Chu B. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study Am Heart J 154 2007 239 246
57. Underhill H.R., Yuan C., and Zhao X.Q. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial Am Heart J 155 2008 584.e1 584.e8
58. Lee J.M., Wiesmann F., and Shirodaria C. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging Atherosclerosis 197 2008 951 958
59. Airan-Javia S.L., Wolf R.L., and Wolfe M.L. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy Am Heart J 157 2009 687.e1 687.e8
60. Miyauchi K., Takaya N., and Hirose T. Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging Circ J 73 2009 111 115